Biomarkers · Renal & Purine

Symmetric Dimethylarginine (SDMA)

Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).

SDMA and risk of death

Published curve higher than the NHANES fitNHANES fit higher

Risk of death relative to the curve's reference value, drawn from the published study (source below).

Published risk of death1.16×per SD increase in serum SDMA (95% CI 1.07–1.25) · Study of Health in Pomerania (SHIP), population-based, 3,952 adults aged 20-81, Germany

SDMA by age and sex

The percentiles as a table

Each row is one sex and age band: the values below which 5%, 25%, 50%, 75% and 95% of people fall (umol/L), from the survey named in the row. Not a reference range or a target.
Sex	Age	5th	25th	Median	75th	95th	n	Cycle / source
All	all	–	0.32	0.37	0.43	–	840	Framingham Offspring r…

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in SDMA, study by study

2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Things that worsen it

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Condition or exposure	Reported effect	Evidence	Source
pharmacologic	Empagliflozin for 6 weeks in adults with type 2 diabetes	Plasma SDMA increased 6.7% after 6 weeks of empagliflozin	RCT	Gessner A, Gemeinhardt A, Bosch A, et al. Cardiovasc Diabetol. 2022.

Sources

Risk curve: Schwedhelm E 2014 (PMID 24819070): all-cause HR 1.16 (1.07-1.25) per SD increase in serum SDMA. Scaled to US values (NHANES).
Schwedhelm E, Wallaschofski H, Atzler D, Dörr M, Nauck M, Völker U, et al. Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in pomerania. PLoS One. 2014;9(5):e96875.

Map Symmetric Dimethylarginine (SDMA) against another biomarker.

Map SDMA against another marker